Multicenter, Randomized, Open Label, Parallel Group Study to Evaluate the Safety and Efficacy of Orsiro Hybrid Drug Eluting Stent

Trial Profile

Multicenter, Randomized, Open Label, Parallel Group Study to Evaluate the Safety and Efficacy of Orsiro Hybrid Drug Eluting Stent

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Apr 2016

At a glance

  • Drugs Sirolimus (Primary) ; Zotarolimus
  • Indications Angina pectoris; Coronary artery disease; Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms ORIENT
  • Most Recent Events

    • 19 Apr 2016 Status changed from recruiting to completed.
    • 02 May 2013 Planned number of patients changed from 345 to 375 as reported by ClinicalTrials.gov.
    • 17 Apr 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top